Cyclooxygenase-2 – An Imperative Prognostic Biomarker in Oral Squamous Cell Carcinoma- An Immunohistochemical Study

Amit Byatnal, Amit Byatnal, Subhalakshmi Sen, Vasudev Guddattu, Monica Charlotte Solomon

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Oral squamous cell carcinoma (OSCC) is the most common head and neck squamous cell carcinoma (HNSCC) with metastasis and tumor recurrence resulting in 90 % of cancer associated mortality. COX-2, an inflammatory biomarker, has been shown to play a significant role in tumorigenesis of OSCC. To study the expression of COX-2 in OSCC by immunohistochemistry and investigate its association with the clinicopathological parameters including patient survival. A cross sectional study was carried out in 75 histologically confirmed cases of OSCC. COX-2 expression was evaluated by indirect streptavidin biotin method. The expression was semi-quantitatively assessed using established criteria. The expression profile of COX-2 was correlated with the clinicopathological details like tumor size, regional lymphnode metastasis, distant metastasis, clinical stage, local recurrence of tumor, histological grade, and survival of patient. Chi square and Kaplan Meier statistical tests were applied for assessing this association. COX-2 expression was absent in normal oral mucosa. Over expression of COX-2 was seen in 58 out of 75 specimens of OSCC. Overexpression of COX-2 was significantly associated with the lymphnode involvement, histological grade, local recurrence of tumor and patient survival. COX-2 expression represents an important biomarker of prognostic significance that may be used to identify a subset of patients at high risk and to predict patient survival.

Original languageEnglish
Pages (from-to)1123-1131
Number of pages9
JournalPathology and Oncology Research
Volume21
Issue number4
DOIs
Publication statusPublished - 28-09-2015

Fingerprint

Cyclooxygenase 2
Squamous Cell Carcinoma
Biomarkers
Survival
Neoplasms
Neoplasm Metastasis
Recurrence
Streptavidin
Kaplan-Meier Estimate
Mouth Mucosa
Biotin
Carcinogenesis
Cross-Sectional Studies
Immunohistochemistry
Mortality

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine
  • Oncology
  • Cancer Research

Cite this

@article{fd362b0792ef44d78a161a370c752736,
title = "Cyclooxygenase-2 – An Imperative Prognostic Biomarker in Oral Squamous Cell Carcinoma- An Immunohistochemical Study",
abstract = "Oral squamous cell carcinoma (OSCC) is the most common head and neck squamous cell carcinoma (HNSCC) with metastasis and tumor recurrence resulting in 90 {\%} of cancer associated mortality. COX-2, an inflammatory biomarker, has been shown to play a significant role in tumorigenesis of OSCC. To study the expression of COX-2 in OSCC by immunohistochemistry and investigate its association with the clinicopathological parameters including patient survival. A cross sectional study was carried out in 75 histologically confirmed cases of OSCC. COX-2 expression was evaluated by indirect streptavidin biotin method. The expression was semi-quantitatively assessed using established criteria. The expression profile of COX-2 was correlated with the clinicopathological details like tumor size, regional lymphnode metastasis, distant metastasis, clinical stage, local recurrence of tumor, histological grade, and survival of patient. Chi square and Kaplan Meier statistical tests were applied for assessing this association. COX-2 expression was absent in normal oral mucosa. Over expression of COX-2 was seen in 58 out of 75 specimens of OSCC. Overexpression of COX-2 was significantly associated with the lymphnode involvement, histological grade, local recurrence of tumor and patient survival. COX-2 expression represents an important biomarker of prognostic significance that may be used to identify a subset of patients at high risk and to predict patient survival.",
author = "Amit Byatnal and Amit Byatnal and Subhalakshmi Sen and Vasudev Guddattu and Solomon, {Monica Charlotte}",
year = "2015",
month = "9",
day = "28",
doi = "10.1007/s12253-015-9940-9",
language = "English",
volume = "21",
pages = "1123--1131",
journal = "Pathology and Oncology Research",
issn = "1219-4956",
publisher = "Springer Netherlands",
number = "4",

}

Cyclooxygenase-2 – An Imperative Prognostic Biomarker in Oral Squamous Cell Carcinoma- An Immunohistochemical Study. / Byatnal, Amit; Byatnal, Amit; Sen, Subhalakshmi; Guddattu, Vasudev; Solomon, Monica Charlotte.

In: Pathology and Oncology Research, Vol. 21, No. 4, 28.09.2015, p. 1123-1131.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Cyclooxygenase-2 – An Imperative Prognostic Biomarker in Oral Squamous Cell Carcinoma- An Immunohistochemical Study

AU - Byatnal, Amit

AU - Byatnal, Amit

AU - Sen, Subhalakshmi

AU - Guddattu, Vasudev

AU - Solomon, Monica Charlotte

PY - 2015/9/28

Y1 - 2015/9/28

N2 - Oral squamous cell carcinoma (OSCC) is the most common head and neck squamous cell carcinoma (HNSCC) with metastasis and tumor recurrence resulting in 90 % of cancer associated mortality. COX-2, an inflammatory biomarker, has been shown to play a significant role in tumorigenesis of OSCC. To study the expression of COX-2 in OSCC by immunohistochemistry and investigate its association with the clinicopathological parameters including patient survival. A cross sectional study was carried out in 75 histologically confirmed cases of OSCC. COX-2 expression was evaluated by indirect streptavidin biotin method. The expression was semi-quantitatively assessed using established criteria. The expression profile of COX-2 was correlated with the clinicopathological details like tumor size, regional lymphnode metastasis, distant metastasis, clinical stage, local recurrence of tumor, histological grade, and survival of patient. Chi square and Kaplan Meier statistical tests were applied for assessing this association. COX-2 expression was absent in normal oral mucosa. Over expression of COX-2 was seen in 58 out of 75 specimens of OSCC. Overexpression of COX-2 was significantly associated with the lymphnode involvement, histological grade, local recurrence of tumor and patient survival. COX-2 expression represents an important biomarker of prognostic significance that may be used to identify a subset of patients at high risk and to predict patient survival.

AB - Oral squamous cell carcinoma (OSCC) is the most common head and neck squamous cell carcinoma (HNSCC) with metastasis and tumor recurrence resulting in 90 % of cancer associated mortality. COX-2, an inflammatory biomarker, has been shown to play a significant role in tumorigenesis of OSCC. To study the expression of COX-2 in OSCC by immunohistochemistry and investigate its association with the clinicopathological parameters including patient survival. A cross sectional study was carried out in 75 histologically confirmed cases of OSCC. COX-2 expression was evaluated by indirect streptavidin biotin method. The expression was semi-quantitatively assessed using established criteria. The expression profile of COX-2 was correlated with the clinicopathological details like tumor size, regional lymphnode metastasis, distant metastasis, clinical stage, local recurrence of tumor, histological grade, and survival of patient. Chi square and Kaplan Meier statistical tests were applied for assessing this association. COX-2 expression was absent in normal oral mucosa. Over expression of COX-2 was seen in 58 out of 75 specimens of OSCC. Overexpression of COX-2 was significantly associated with the lymphnode involvement, histological grade, local recurrence of tumor and patient survival. COX-2 expression represents an important biomarker of prognostic significance that may be used to identify a subset of patients at high risk and to predict patient survival.

UR - http://www.scopus.com/inward/record.url?scp=84940447315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940447315&partnerID=8YFLogxK

U2 - 10.1007/s12253-015-9940-9

DO - 10.1007/s12253-015-9940-9

M3 - Article

VL - 21

SP - 1123

EP - 1131

JO - Pathology and Oncology Research

JF - Pathology and Oncology Research

SN - 1219-4956

IS - 4

ER -